[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334633-105":59,"doc-detail-334633-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","viewing-the-immune-checkpoint-vista-landscape-and-outcomes-across-cancers","Viewing the immune checkpoint VISTA - landscape and outcomes across cancers","","Immune checkpoint inhibitor therapy may require identifying actionable checkpoint pathways through immune profiling. This study analyzed transcriptomic expression and clinical correlates of V-domain immunoglobulin suppressor of T-cell activation (VISTA) across diverse advanced and metastatic cancers. RNA sequencing of 514 tissues quantified VISTA alongside eight immune checkpoint markers and assessed clinical outcomes. High VISTA RNA expression related to multiple checkpoint-associated molecules and showed poorer post-immunotherapy survival in pancreatic cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/viewing-the-immune-checkpoint-vista-landscape-and-outcomes-across-cancers/334633/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/viewing-the-immune-checkpoint-vista-landscape-and-outcomes-across-cancers/334633.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was VISTA expression assessed in this study?","Question",{"text":112,"@type":113},"RNA sequencing was performed on 514 tissues from diverse advanced/metastatic cancers, quantifying VISTA and eight other immune checkpoint markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What associations were observed between high VISTA expression and other checkpoint molecules?",{"text":117,"@type":113},"High VISTA RNA expression correlated independently with high BTLA, TIM-3, and TNFRSF14 expression.",{"name":119,"@type":110,"acceptedAnswer":120},"Did VISTA expression predict outcomes for patients receiving immunotherapy?",{"text":121,"@type":113},"Across the pan-cancer ICI-treated cohort, VISTA transcript levels did not correlate with progression-free survival or overall survival. In ICI-treated pancreatic cancer patients, high VISTA was associated with significantly shorter median overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334633,1790192509,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ORIGINAL RESEARCH  \nViewing the immune checkpoint VISTA: landscape and outcomes across cancers  \nD. Nishizaki1􀀁y, R. Kurzrock2, 3y, H. Miyashita4, J. J. Adashek5, S. Lee1, M. Nikanjam1, R. N. Eskander6, H. Patel1, G. P. Botta1,  \nM. K. Nesline7, S. Pabla7, J. M. Conroy7, P. DePietro7, J. K. Sicklick8 & S. Kato1 􀀁  \n1Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla; 2MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, USA; 3WIN Consortium, Paris, France; 4Dartmouth Cancer Center, Hematology and Medical Oncology, Lebanon; 5Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore; 6Center for Personalized Cancer Therapy and Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Diego, Moores Cancer Center, La Jolla; 7OmniSeq Inc., Buffalo; 8Division of Surgical Oncology, Department of Surgery, Center for Personalized Cancer Therapy, University of California San Diego, La Jolla, USA  \nAvailable online xxx  \nBackground: Optimizing immune checkpoint inhibitor (ICI) therapy may require identiﬁcation of co-targetable checkpoint pathways via immune proﬁling. Herein, we analyzed the transcriptomic expression and clinical correlates of V-domain immunoglobulin suppressor of T-cell activation (VISTA), a promising targetable checkpoint.  \nPatients and methods: RNA sequencing was carried out on 514 tissues reﬂecting diverse advanced/metastatic cancers. Expression of eight immune checkpoint markers [lymphocyte-activation gene 3 (LAG-3), tumor necrosis factor receptor superfamily 14 (TNFRSF14), programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), B- and T-lymphocyte attenuator (BTLA), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), cytotoxic T-lymphocyte antigen 4 (CTLA-4)], in addition to VISTA, was analyzed, along with clinical outcomes.  \nResults: High VISTA RNA expression was observed in 32% of tumors (66/514) and was the most common highly expressed checkpoint among the nine assessed. High VISTA expression was independently correlated with high BTLA, TIM-3, and TNFRSF14, and with a diagnosis of pancreatic, small intestine, and stomach cancer. VISTA transcript levels did not correlate with overall survival (OS) from metastatic/advanced disease in the pan-cancer cohort or with immunotherapy outcome (progression-free survival and OS from the start of ICI) in 217 ICI-treated patients. However, in ICI-treated pancreatic cancer patients (n ¼ 16), median OS was signiﬁcantly shorter (from immunotherapy initiation) for the high- versus not-high-VISTA groups (0 . 28 versus 1 . 21 years) (P ¼ 0.047); in contrast, VISTA levels were not correlated with OS in 36 pancreatic cancer patients who did not receive ICI. Conclusion: High VISTA expression correlates with high BTLA, TIM-3, and TNFRSF14 checkpoint-related molecules and with poorer post-immunotherapy survival in pancreatic cancer, consistent with prior literature indicating that VISTA is prominently expressed on CD68þ macrophages in pancreatic cancers and requiring validation in larger prospective studies. Immunomic analysis may be important for individualized precision immunotherapy.  \nKey words: precision medicine, gene expression proﬁling, neoplasms, immunotherapy, immune checkpoint inhibitors  \n*Correspondence to: Dr Shumei Kato, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, 3855 Health Science Drive, La Jolla, CA 92037, USA. Tel: þ858-822-2372; Fax: 858-822-6186  \nE-mail: [smkato@health.ucsd.edu](smkato@health.ucsd.edu) (S. Kato).  \nDr Daisuke Nishizaki, Center for Personalized Cancer Therapy and Divis","cbCaiqZuALdkqo05","https://ap.wps.com/l/cbCaiqZuALdkqo05","pdf",557731,11,"English","# Background\n# Patients and methods\n# Results\n# Conclusion\n# Introduction\n# Key words","[{\"question\":\"How was VISTA expression assessed in this study?\",\"answer\":\"RNA sequencing was performed on 514 tissues from diverse advanced/metastatic cancers, quantifying VISTA and eight other immune checkpoint markers.\"},{\"question\":\"What associations were observed between high VISTA expression and other checkpoint molecules?\",\"answer\":\"High VISTA RNA expression correlated independently with high BTLA, TIM-3, and TNFRSF14 expression.\"},{\"question\":\"Did VISTA expression predict outcomes for patients receiving immunotherapy?\",\"answer\":\"Across the pan-cancer ICI-treated cohort, VISTA transcript levels did not correlate with progression-free survival or overall survival. In ICI-treated pancreatic cancer patients, high VISTA was associated with significantly shorter median overall survival.\"}]","Viewing the immune checkpoint VISTA - landscape and outcomes across cancers | PDF",1790007584,28]